Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 1/20 | 0.41 |
| ▸ | MGMT | P16455 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032108 | 0.88 | HSPB1 (0.39) | HSPB1KMT2AMEN1MAPTCYP19A1 | |
| SCHEMBL4031174 | 0.82 | MEN1 (0.45) | MGMTKMT2AMEN1MAPTCYP19A1 | |
| SCHEMBL8810435 | 0.77 | MAPT (0.55) | HSPB1MGMTKMT2AMEN1MAPT | |
| SCHEMBL4029725 | 0.77 | HSPB1 (0.48) | HSPB1MGMTKMT2AMEN1MAPT | |
| SCHEMBL4031192 | 0.76 | MEN1 (0.39) | KMT2AMEN1MAPTCYP19A1S1PR4 | |
| SCHEMBL4033792 | 0.76 | AKR1C3 (0.38) | KMT2AMEN1MAPTS1PR4ALDH1A1 | |
| SCHEMBL20302648 | 0.76 | TDP1 (0.53) | KMT2AMEN1MAPTCYP19A1HPGD | |
| SCHEMBL30166675 | 0.76 | TDP1 (0.53) | KMT2AMEN1MAPTCYP19A1HPGD | |
| SCHEMBL643730 | 0.76 | ALDH1A1 (0.49) | KMT2AMEN1MAPTS1PR4SMN1; SMN2 | |
| SCHEMBL2701819 | 0.71 | MEN1 (0.43) | MGMTKMT2AMEN1MAPTCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444210-B1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| US-20050271608-A1 | Skin whitening compositions based on hydroxyaryl alkyl ketones and their isosteric derivatives | GUPTA SHYAM K | 2005-12-08 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| EP-1444210-A1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003040108-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | HSPB1 3772/4885MGMT 1687/4885KMT2A 1693/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | HSPB1 3789/4885MGMT 991/4885KMT2A 1786/4885 |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | HSPB1 3772/4885MGMT 1687/4885KMT2A 1693/4885 |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | HSPB1 3789/4885MGMT 991/4885KMT2A 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.